Comparison of clinical, biochemical, and histological features of 90 Greek and Spanish patients with primary biliary cirrhosis (PBC) according to multiple nuclear dots (MND) and/or rim-like membranous pattern (RL/M) reactivity
| Total PBC (n = 90) | Positive PBC specific ANA (n = 65) | Negative PBC specific ANA (n = 25) | Positive MND (n = 37) | Negative MND (n = 53) | Positive RL/M (n = 42) | Negative RL/M (n = 48) | Positive PBC specific ANA IgG3 (n = 42) | Negative PBC specific ANA IgG3 (n = 48) | |
|---|---|---|---|---|---|---|---|---|---|
| Data are expressed as mean (SD). | |||||||||
| *0.1>p>0.05; **p⩽0.05; ***p⩽0.01; ****p⩽0.005. ¶ | |||||||||
| AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase, γGT, gamma glutamyl transpeptidase; UDCA, ursodeoxycholic acid; nv, normal values; n, no; y, yes. | |||||||||
| Age (y) | 58 (11.8) | 58 (11.5) | 58 (13) | 58 (12.5) | 58 (11.5) | 60 (10.2) | 57 (13) | 59 (9.5) | 57 (13.6) |
| Duration of disease (months) | 48 (61.6) | 52 (50) | 37 (55) | 59 (54)* | 40 (49)* | 49 (53) | 47 (51) | 66 (52.5)**** | 32 (45.7)**** |
| Bilirubin (mg/dl) | 1.3 (1.1) | 1.4 (1.2) | 1 (0.6) | 1.5 (1.2) | 1.1 (1) | 1.5 (1.4) | 1.1 (0.8) | 1.5 (1.3) | 1.1 (0.8) |
| Albumin (g/dl) | 4.1 (0.6) | 4 (0.6) | 4.3 (0.5) | 4 (0.6)* | 4.2 (0.6)* | 4 (0.7) | 4.2 (0.5) | 4 (0.6)* | 4.2 (0.6)* |
| AST (U/l) (nv <40) | 59 (67) | 63 (76) | 48 (27) | 70 (96) | 60 (51) | 71 (94) | 48 (25) | 68 (92) | 51 (30) |
| ALT (U/l) (nv <40) | 66 (62) | 69 (68) | 58 (45) | 74 (75) | 60 (51) | 75 (79) | 58 (42) | 67 (71) | 65 (54) |
| ALP (U/l) (nv <104) | 339 (313) | 318 (290) | 394 (366) | 310 (237) | 360 (357) | 323 (335) | 353 (295) | 375 (330) | 308 (297) |
| γGT (U/l) (nv <50) | 201 (190) | 187 (183) | 235 (207) | 188 (173) | 209 (202) | 182 (182) | 216 (197) | 214 (204) | 189 (179) |
| IgG (mg/dl) (nv <1690) | 1666 (558) | 1677 (561) | 1637 (559) | 1758 (671) | 1600 (456) | 1635 (490) | 1692 (614) | 1772 (593)* | 1571 (511)* |
| IgM (mg/dl) (nv <249) | 387 (249) | 390 (251) | 379 (252) | 394 (269) | 382 (237) | 385 (206) | 389 (284) | 398 (222) | 377 (273) |
| IgA (mg/dl) (nv <300) | 310 (148) | 305 (141) | 324 (170) | 307 (143) | 312 (153) | 311 (151) | 309 (148) | 320 (134) | 301 (161) |
| Creatinine (mg/dl) | 0.9 (0.4) | 0.9 (0.4) | 0.8 (0.2) | 0.9 (0.4) | 0.8 (0.3) | 0.9 (0.4) | 0.9 (0.3) | 0.9 (0.5) | 0.8 (0.2) |
| Mayo risk score | 4.9 (1.5) | 5 (1.6) | 4.5 (0.9) | 5.2 (1.8) | 4.6 (1.1) | 5.2 (1.7) | 4.6 (1.2) | 5.2 (1.7)* | 4.6 (1.2)* |
| Histological stage | 2.4 (1.2) | 2.6 (1.2)**** | 1.8 (0.9)**** | 2.7 (1.2)* | 2.1 (1.1)* | 2.7 (1.1)** | 2.1 (1.2)** | 2.7 (1.1)*** | 2 (1.1)*** |
| Histological stage (I-III/IV) | 68/20 | 45/19**** | 23/1**** | 22/14*** | 46/6*** | 29/12 | 39/8 | 28/14* | 39/7* |
| Non cirrhotic/cirrhotic | 69/21 | 45/20**** | 24/1**** | 22/15**** | 47/6**** | 30/12 | 39/9 | 28/14* | 41/7* |
| Liver related deaths or transplantation (n/y) | 76/14 | 52/13* | 24/1* | 26/11**** | 50/3**** | 35/7 | 41/7 | 32/10* | 44/4* |